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Evasion of apoptosis is one of the hallmarks of hu-
man cancers contributing to tumor formation and 
treatment resistance. The alterations in apoptosis 
signaling pathway often occur in drug-resistant cancer 
cells. In particular, defective apoptosis signaling may 
be caused by an increase in content of anti-apoptotic 
molecules and/or by a decreased content or impaired 
function of pro-apoptotic proteins. Thus, identification 
of novel substances for overcoming the drug resis-
tance has gained much attention in cancer therapy.
Chemosensitivity of cancer cells to cytotoxic drugs 
has been attributed partially to their ability to trigger 
apoptosis. The natural multi-targeted agents such as 
flavonoids are considered at present as the poten-
tial sensitizers for apoptosis induced by a variety of 
anticancer drugs, which might be advantageous for 
achieving better treatment outcome in cancer patients 
[1]. Quercetin, one of the most widely distributed 
flavonoids in nature, has been reported to induce cell 
cycle arrest and apoptosis in human leukemia and 
lymphoma cells [2–6]. Several mechanisms of the 
apoptogenic effects of quercetin have been suggest-
ed, with death receptor-5, anti-apoptotic Bcl-2 and 
Bcl-xL proteins, caspases, Akt/PKB kinase, Cu-Zn 
superoxide dismutase and heat shock proteins being 
among the cellular targets [7, 8]. In particular setting, 
quercetin was demonstrated to modify the phenotype 
of drug resistance in leukemic cells [9, 10]. Neverthe-
less, little is known on the cross resistance between cy-
totoxic chemotherapeutical agents and such unrelated 
substances as natural flavonoids. Therefore, analysis 
of apoptosis induction by flavonoids in drug-resistant 
and drug-sensitive cells may be advantageous for 
better understanding of the mechanisms of drug re-
sistance as well as providing the clues for developing 
approaches aimed at utilizing the potential of these 
substances in overcoming drug resistance.
The aim of the study was to compare the effects of 
the conventional cytotoxic drug, vepeside and natural 
flavonoid, quercetin in Jurkat cells and their multidrug 
resistant subline Jurkat/A4, in particular to analyze the 
effector mechanisms of apoptosis and the patterns of 
several pro- and antiapoptotic proteins in these cells 
upon exposure to vepeside or quercetin.
MATERIALS AND METHODS
Chemicals and antibodies. Quercetin purchased 
from Sigma (USA) was dissolved in 96% ethanol and 
diluted in culture medium, with final concentration of 
ethanol being less than 0.1%. Vepeside was purchased 
from Brystol-Myers Squibb SpA (Italy). Anti-caspase-8 
(clone 5F7 recognizing the proform of caspase-8) and 
anti-caspase-9 (clone 5В4) monoclonal antibo dies 
(mAbs) were obtained from Immunotech (France). Anti-
caspase-3 (clone 84803.111) and anti--actin (clone 
AC-15) mAbs were from Sigma. Anti-BNip1 (Bcl-2 
Nineteen kilodalton interacting protein 1; clone 5), 
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anti-CAS (Crk-associated substrate; clone 24), anti-
XIAP (X-linked inhibitor of apoptosis; clone 28) and 
anti-Bad (clone 48) mAbs were from BD Pharmingen 
Transduction Laboratories (USA). The HRP-conjugated 
goat anti-mouse antibody was from Promega (USA).
Cell culture and treatment. Jurkat cell line originally 
derived from the peripheral blood of a 14-year-old boy 
with acute lymphoblastic leukemia [11] was obtained 
from the National Collection of Cell Lines of the Institute 
of Experimental Pathology, Oncology and Radiobio-
logy (Kyiv, Ukraine). The CD95-deficient cell clone 
Jurkat/A4 was derived from the Jurkat cell line by se-
rial treatment with apoptosis-inducing anti-CD95 mAb 
(clone IPO-4, class IgM) [12]. The cells were maintained 
at 37 °С in an atmosphere of 95% air and 5% СО2 as sus-
pension cultures in RPMI-1640 medium supplemented 
with 10% fetal calf serum. The cultures were passaged 
every 3–4 days upon reaching maximum cell density. 
Quercetin was added to the cells at exponential growth 
phase. Cell growth and viability were assessed by direct 
counting of trypan blue dye-excluding cells.
Flow cytometric analysis. The cells were resus-
pended in hypotonic buffer containing 0.1% sodium 
citrate, 0.1% Triton X-100, 5 g/ml propidium iodide. 
250 g/ml of RNAse A was added to each cell sample, 
and the cells were stained for 15 min at 37 °C. Flow cy-
tometry was performed on a FACSCalibur automated 
system (Becton Dickinson, USA) and data were ana-
lyzed using CellQuest software package and ModFit LT 
2.0 program. The dead cells and debris were eliminated 
from the analysis based on forward and sideways light 
scattering. The percentage of cells containing cleaved 
form of PARP (poly(ADP-ribose) polymerase) was as-
sessed by flow cytometry using FITC-conjugated mAb 
(clone F21–852; BD Biosciences). This antibody reacts 
only with the 89-kDa fragment of human PARP-1 pro-
duced by caspase cleavage.
SDS-PAGE and Western blotting. All cells were 
washed twice with ice-cold PBS and then lysed in lysis 
buffer containing 20 mM Tris-HCl (pH 7.4), 1% Triton 
X-100, 150 mM NaCl with freshly added protease in-
hibitor mixture (Roche, Germany) for 30 min at 4 °C. 
Protein samples were collected from supernatant after 
centrifugation of the samples at 12,000 x g for 15 min. 
The aliquots of lysates were mixed with 5× sample 
buffer containing 2-mercaptoethanol and boiled for 
5 min before loading on sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Following 
SDS-PAGE separation, proteins were transferred to 
PVDF membrane (Immobilon-P, Millipore, USA). The 
membrane was blocked for 1 h at RT with 5% skim 
milk in PBS containing 0.05% Tween 20. The blots 
were incubated for 1 h at RT with an appropriate dilu-
tion of primary antibodies followed by their incubation 
with HRP-conjugated goat anti-mouse antibody for 
1 h. After washing four times for 10 min each by PBS-
Tween 20, the proteins were visualized by enhanced 
chemiluminescence (ECL) detection system (Amer-
sham Pharmacia, UK) and Agfa X-ray film. For each 
immunoblot, equal loading of protein was confirmed 
by reprobing it with anti-actin mAb.
Statistical analysis. Each experiment was repli-
cated three times. The results of the experimental and 
control groups were tested for statistical significance 
by a one-tailed Student’s t test.
RESULTS
Effects of quercetin on cell growth and apop-
tosis induction in Jurkat and Jurkat/A4 cells. 
In contrast to the parental Jurkat cell line, survival 
of Jurkat/A4 cells is only slightly changed after ex-
posure to vepeside or quercetin (Fig. 1). Therefore, 
Jurkat/A4 cells demonstrate the resistance not only 
to vepeside but also to quercetin. When the fraction 
of hypodiploid cells is analyzed, both vepeside and 
quercetin, in fact, induces apoptosis in the initial Jur-
kat cells and in the resistant clone as well (Fig. 2, a). 
Nevertheless, apoptosis induction in a fraction of 
resistant cells does not affect the following survival of 
cells in contrast to their initial counterpart.
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Fig. 1. Growth kinetics of Jurkat (a) and Jurkat/A4 cells (b) 
treated with vepeside or quercetin. Each time point represents 
the means ± S.D. of triplicate samples
Effects of quercetin on cell cycle progression 
in Jurkat and Jurkat/A4 cells. Both Jurkat and Jur-
kat/A4 cells show the similar patterns of redistribution 
in cell cycle phases upon the exposure to vepeside, 
namely the extensive cell arrest in G0/G1 is evident at 
the concentration of 2 M(Fig. 3). Similarly, the effects 
of quercetin are essentially the same for both cell lines, 
namely the significant increase in cell population in G2/M 
phase (see Fig. 3). This increase in G2/M cell popula-
tion is accompanied with a concomitant decrease in 
G0/G1-phase in Jurkat cells, while in Jurkat/A4 line both 
G0/G1- and S-phase percentage is reduced.
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Fig. 2. Induction of apoptosis (a) and PARP cleavage (b) in 
Jurkat and Jurkat/А4 cells treated with vepeside or quercetin.
1, 4  — control; 2, 5 — 2 M vepeside, 24 h; 3, 6 — 40 M quer-
cetin, 48 h. Each experiment was done in triplicate. The figures 
show a representative staining profile for 10,000 cells per ex-
periment. M1 comprises the hypodiploid cells in (a) and cleaved 
PARP-positive cells in (b). The percentage of sub-G1 cells or 
cleaved PARP-positive cells is given in each plot
Caspase-9 and -3 activation and PARP cleav-
age in Jurkat and Jurkat/A4 cells treated with 
vepeside or quercetin. The appearance of the active 
form of caspase-9 in Jurkat cells treated with vepeside 
or quercetin is evident (Fig. 4, a). Vepeside treatment 
activates reduced levels of caspase-9 in Jurkat/A4 cells 
as compared with that in parental Jurkat cells (see 
Fig. 4, a). The effect of quercetin on the activation 
of caspase-9 in resistant cells is negligible. In Jurkat 
cells, vepeside treatment results in decreasing level 
of procaspase-3 with accompanying appearance of 
the processed form (see Fig. 4, a). In Jurkat/A4 cells, 
in the immunoblot the slight band of the active form of 
caspase-3 is discernible. The treatment with vepeside 
or quercetin does not increase the intensity of the 
band in comparison with the initial one (see Fig. 4, a). 
As shown in Figure 2, b, treatment of Jurkat cells with 
vepeside or quercetin results in increased PARP cleav-
age. In comparison, no PARP cleavage is found in the 
Jurkat/A4 cells.
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Fig. 3. Cell cycle distribution in Jurkat and Jurkat/А4 cells 
treated with vepeside or quercetin. After staining with propidium 
iodide, cells were analyzed by flow cytometry. The percentage 
of cells in G1 (white bars), S (grey bars) or G2/M phase (dark 
bars) are shown
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Fig. 4. Expression of caspases (a) and apoptosis-related pro-
teins (b) in Jurkat and Jurkat/А4 cells treated with vepeside or 
quercetin. 1, 4 — control; 2, 5 — 2 M vepeside; 3, 6 — 40 M 
quercetin. Total cell lysates were prepared in SDS-Laemmli 
sample buffer and extracts were analyzed by Western blotting. 
Levels of β-actin are shown as the loading control
Procaspase-8 in Jurkat and Jurkat/A4 cells 
treated with vepeside or quercetin. The reduced ex-
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pression of procaspase-8 is evident in Jurkat cells upon 
vepeside but not quercetin treatment. The effects of 
both vepeside and quercetin on the procaspase-8 level 
in Jurkat/A4 are insignificant (see Fig. 4, a).
Pro- and antiapoptotic proteins in Jurkat and 
Jurkat/A4 cells. The expression profiles of several 
apoptosis-related proteins were studied in Jurkat and 
Jurkat/A4 cells by Western blotting. The expression 
of Bad and BNip1 proteins in Jurkat/A4 cells is lower 
than in the parental cell line. At the same time, Bad and 
BNip1expression increases upon vepeside or querce-
tin treatment of Jurkat cells. Jurkat/A4 cells express 
more XIAP and CAS than parental Jurkat cells. Upon 
apoptosis induction with vepeside, XIAP and CAS levels 
in Jurkat cells decrease, this effect being negligible in 
resistant cells (see Fig. 4, b).
DISCUSSION
The serial treatment of Jurkat cells with the agonistic 
anti-CD95 mAb resulted in cross-resistance to cytotoxic 
substances [12], although other authors demonstrated 
that Jurkat cells resistant to CD95 and the parental 
cells were equally susceptible to anticancer drugs [13]. 
The appearance of drug resistance in cells selected 
for resistance to CD95-mediated apoptosis has been 
quite unexpectedly shown also in another T-cell line 
[14]. While CD95-deficient Jurkat/A4 cell line has been 
shown to possess cross-resistance to various unrelated 
cytotoxic agents including different anticancer drugs 
[15, 16], the underlying mechanisms of such multidrug 
resistance have not been completely elucidated. Seve-
ral mechanisms have been proposed to be involved in 
the development of resistant phenotype of Jurkat/A4 as 
well as other resistant cell lines [16, 17]. It would be of 
interest to analyze the effector mechanisms of apop-
tosis and the profile of pro- and antiapoptotic proteins 
in the initial Jurkat cells and Jurkat/A4 cells with the 
phenotype of multiple drug resistance.
The typical mitochondrial apoptotic pathway is 
evident in Jurkat cells exposed to inhibitor of DNA 
topoisomerase II with activation of apical caspase-9 and 
effector caspase-3 and the cleavage of PARP as cas-
pase substrate. The same features have been revealed 
in Jurkat cells treated with quercetin. Therefore, in 
addition to the cross-resistance of Jurkat/A4 cells to 
various unrelated chemotherapeutics demonstrated 
earlier [12], the present study reveales the resistance 
of Jurkat/A4 cells to the natural flavonoid. Quercetin as 
well as several other flavonoids is capable of inducing 
cytochrome c-dependent apoptosis with caspase-3 ac-
tivation in variuos lines of leukemic cells [3, 4]. While in 
our study vepeside and quercetin initially induce apop-
tosis in both cell lines, the parameters of cytotoxicity 
and further viability of the parental and resistant cells 
differ drastically. In resistant cells, the increment in the 
percentage of hypodiploid cells upon the exposure to 
vepeside is less than in the initial Jurkat cells. Vepeside 
treatment activates reduced levels of caspase-9 and 
-3 in Jurkat/A4 cells as compared with that in parental 
Jurkat cells. The effect of quercetin on the activation of 
caspase-9 and -3 in resistant cells is negligible and the 
cleaved form of PARP is detectable in quercetin-treated 
Jurkat but not Jurkat/A4 cells.
The expression of CD95 in Jurkat/A4 cells, which 
are resistant to CD95-mediated apoptosis, is very low 
in comparison with the parental Jurkat cells (1–6% vs 
70–80%) [12]. The processing of caspase-8 has been 
proved to accompany the mitochondrial pathway of 
apoptosis induced by various cytotoxic drugs, which 
is not necessarily required for drug-induced apoptosis 
per se [18]. In such setting, caspase-8 functions rather 
as an effector caspase in the mitochondrial pathway. 
We have shown the reduction in the content of 57-kDa 
proform of caspase-8 in Jurkat cells exposed to ve-
peside. This fact indirectly points to the processing of 
caspase-8 corroborating the data presented elsewhere 
[19]. Therefore, caspase-8 is activated by chemothera-
peutic substances in the absence of a death receptor 
signaling. The level of procaspase-8 in resistant cells 
remains unchanged upon the exposure to vepeside. 
In contrast, the level of procaspase-8 remains un-
changed in both Jurkat and Jurkat/A4 cells treated with 
quercetin. These results are in line with the absence 
of caspase-8 processing in the setting of quercetin-
induced apoptosis in human hepatoma cells [20].
The drug resistance of cancer cells is a complex 
phenomenon comprising different intracellular pro-
cesses. We have attempted to analyze the expression 
profile of several apoptosis-related proteins with the 
aim of evaluating the determinants of vepeside and 
quercetin resistance in Jurkat/A4 cells, in particular 
Bcl-2-related proteins, Bad and BNip-1, and the 
proteins with antiapoptotic properties, XIAP and CAS.
Bcl-2 family proteins are known to play a central role 
in apoptosis regulation. We have analyzed the expres-
sion of Bad as proapoptotic protein of Bcl-2 family and 
another proapoptotic protein BNip1. Both proteins 
belong to BH3-only proteins. The expression of Bad 
and BNip1 proteins in Jurkat/A4 cells turned out to be 
inferior to that in the parental Jurkat cell line. Therefore, 
the resistance phenotype in Jurkat/A4 cells is charac-
terized by the reduced expression of both proapop-
totic proteins. Upon the exposure both to vepeside and 
quercetin, the content of Bad and BNip1 proteins tends 
to increase in Jurkat cells while in Jurkat/A4 cells the 
levels of both proapoptotic proteins remain practically 
the same as in the cells without treatment.
On the other hand, expression profile of Jurkat/
A4 cells is characterized by the increased level of XIAP 
representing one of the most potent endogenous in-
hibitor of caspases (both apical and effector ones). Our 
findings are in agreement to those of Wang et al. [21], 
who reported that drug resistant phenotype in U937 
cells is associated with upregulation of XIAP. Increased 
CAS expression also is known to be associated with the 
resistance of cancer cells to chemotherapy (reviewed 
in [22]). In our study, the expression profile of Jurkat/
A4 cells is characterized by the increase in CAS level.
To sum up, our data suggest that in Jurkat leukemia 
cells quercetin induces apoptosis mainly through a mi-
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tochondrial-mediated pathway. Multidrug-resistant 
Jurkat/A4 cells are also resistant to cytotoxic effects of 
quercetin. The expression profile of Jurkat/A4 cells is 
characterized by the increased levels of XIAP and CAS 
representing the endogenous inhibitors of apoptosis. 
Further elucidation of the apoptotic pathways involved 
in resistance of Jurkat/A4 cells to chemotherapeutics 
will assist in designing more effective strategies to 
overcome drug resistance in cancer cells.
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